Summary: Genmab's management will attend the Merrill Lynch Pan European Biotech
and Medical Devices One-on-One Forum on May 15 and the 2008 Citi Investment
Research Global Health Care Conference on May 21, 2008.
Copenhagen, Denmark; May 6, 2008 - Genmab A/S (OMX: GEN) announced today its
management will attend two investor conferences in May 2008. Professor Jan van
de Winkel, President, Research & Development & Chief Scientific Officer and
Chief Operating Officer, Claus Møller will attend the Merrill Lynch Pan European
Biotech and Medical Devices One-on-One Forum in London, UK on May 15. Lisa N.
Drakeman, Ph.D., Chief Executive Officer of Genmab, will present at the 2008
Citi Investment Research Global Health Care Conference in New York, NY, USA on
May 21 at 11:30AM EDT. Dr. Drakeman's presentation will be available via live
and archived webcast at www.genmab.com.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using cutting-edge
antibody technology, Genmab's world class discovery, development and
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders. As Genmab advances towards a commercial future, we remain committed
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Investor News No. 05/2008
###
